Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Targovax ASA ( (GB:0RIS) ) just unveiled an update.
Circio Holding ASA has disclosed that a closely associated company of its CFO, Lubor Gaal, has exercised 65,164 subscription rights and additionally subscribed for 204,836 offer shares without subscription rights in the ongoing rights issue, for a total of 270,000 new shares at NOK 1.00 per share, with the same number of warrants potentially allocated subject to board approval and completion of the offering. The insider participation underscores management’s support for the capital raise, which is being conducted under Norwegian securities regulations and the EU Market Abuse Regulation, signaling internal confidence in the company’s financing plan and future prospects while providing transparency to existing and prospective shareholders.
More about Targovax ASA
Circio Holding ASA is a listed Norwegian company, previously known as Targovax ASA, operating in the biopharmaceutical sector. The company focuses on developing innovative drug candidates and related technologies, and it finances its activities through equity market transactions such as rights issues directed at existing shareholders and new investors.
Average Trading Volume: 3,883,209
Current Market Cap: NOK204.9M
Find detailed analytics on 0RIS stock on TipRanks’ Stock Analysis page.